The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders
- 26 April 2010
- journal article
- review article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 95 (10), 1769-1777
- https://doi.org/10.3324/haematol.2010.023689
Abstract
The Epstein-Barr virus has evolved a plethora of strategies to evade immune system recognition and to establish latent infection in memory B cells, where the virus resides lifelong without any consequence in the majority of individuals. However, some imbalances in the equilibrium between the inherent virus transforming properties and the host immune system can lead to the development of different tumors, such as lymphoproliferative disorders, Hodgkin's lymphoma, Burkitt's lymphoma, and nasopharyngeal carcinoma. The expression of viral antigens in malignant cells makes them suitable targets for immunotherapeutic approaches, which are mainly based on the ex vivo expansion of EBV-specific T cells. Indeed, the infusion of virus-specific cytotoxic T lymphocytes has proved not only to be safe and effective, but also capable of restoring or inducing a protective anti-virus immunity, which is lacking, albeit to a different extent, in every EBV-driven malignancy. The purpose of this review is to summarize the results of adoptive immunotherapy approaches for EBV-related malignancies, with particular emphasis on the immunological and virological aspects linked to the clinical responses obtained. Data collected confirm the clinical relevance of the use of EBV-specific cytotoxic T lymphocytes in the field of adoptive immunotherapy and suggest the increasing importance of this approach also against other tumors, concurrent with the increasing knowledge of the intimate and continuous interplay between the virus and the host immune systemKeywords
This publication has 100 references indexed in Scilit:
- Children with endemic Burkitt lymphoma are deficient in EBNA1‐specific IFN‐γ T cell responsesInternational Journal of Cancer, 2009
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNature Medicine, 2008
- Patients with Epstein Barr virus‐positive lymphomas have decreased CD4+ T‐cell responses to the viral nuclear antigen 1International Journal of Cancer, 2008
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1The New England Journal of Medicine, 2008
- Spontaneous T cell responses to Epstein‐Barr virus‐encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapyInternational Journal of Cancer, 2008
- Adoptive cell transfer: a clinical path to effective cancer immunotherapyNature Reviews Cancer, 2008
- The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphomaProceedings of the National Academy of Sciences of the United States of America, 2007
- A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primatesThe Journal of Experimental Medicine, 2007
- Increase in circulating Foxp3+CD4+CD25high regulatory T cells in nasopharyngeal carcinoma patientsBritish Journal of Cancer, 2007
- Adoptive immunotherapy for cancer: building on successNature Reviews Immunology, 2006